Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Boston Scientific (BSX)

Tipranks - Tipranks - Mon Mar 23, 9:10AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on enGene Holdings (ENGN) and Boston Scientific (BSX).

Claim 30% Off TipRanks Premium

enGene Holdings (ENGN)

UBS analyst David Dai maintained a Hold rating on enGene Holdings on March 20 and set a price target of $9.00. The company’s shares closed last Friday at $7.21.

According to TipRanks.com, Dai is a 3-star analyst with an average return of 4.2% and a 51.6% success rate. Dai covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Iovance Biotherapeutics, and Telix Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for enGene Holdings with a $23.29 average price target, representing a 223.9% upside. In a report issued on March 5, TipRanks – xAI also reiterated a Hold rating on the stock with a $10.00 price target.

See today’s best-performing stocks on TipRanks >>

Boston Scientific (BSX)

Citi analyst Joanne Wuensch maintained a Buy rating on Boston Scientific on March 20 and set a price target of $94.00. The company’s shares closed last Friday at $69.48, close to its 52-week low of $66.80.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 2.3% and a 50.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Bausch + Lomb Corporation. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $105.58 average price target, which is a 51.3% upside from current levels. In a report issued on March 9, TD Cowen also maintained a Buy rating on the stock with a $100.00 price target.

Read More on ENGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).